We are a venture backed company with a mission to develop first-in-class and best-in-class antibody based targeted therapies against membrane and extracellular proteins that drive underlying disease biology. Protein degradation has the potential to eliminate disease causing proteins that were previously not addressable by classical therapeutic approaches. First generation protein degradation approaches can degrade intracellular proteins but do not address membrane and extracellular proteins, which are approximately 40% of the proteome. Our proprietary EpiTAC platform enables the development of first-in-class and best-in-class targeted therapies that degrade disease driving membrane and extracellular proteins. This approach can be effective against a wide range of disorders that lack meaningful treatment options today.